Ionis Plunges After Phase 3 Miss; Investigation Adds Noise

What happened

Ionis Pharmaceuticals shares fell over 20% on July 9, 2026, after the Phase 3 CARDIO-TTRansform trial of eplontersen (partnered with AstraZeneca) failed to meet its primary endpoint, wiping out a key pipeline bet. Management reaffirmed full-year 2026 guidance in the subsequent 8-K, signaling that the miss does not alter near-term financial expectations for its owned products. By July 13, a securities investigation was announced by Levi & Korsinsky, a routine plaintiff-lawyer reaction to the share drop that poses no immediate business risk. The investment thesis now rests almost entirely on the commercial ramp of TRYNGOLZA (approved for sHTG in June 2026) and the upcoming PDUFA dates for zilganersen (Sept 22) and bepirovirsen (Oct 26). At $58.25, the stock prices in significant pipeline discount, but the $1.9B cash position and evolving commercial base provide a margin of safety if execution holds.

Implication

If TRYNGOLZA sHTG launch shows early demand and net price discipline, the stock can re-rate toward the $66 base case. Failure to support guidance or a zilganersen CRL would push toward $45. The investigation is a sideshow; focus on owned-product execution and September/October catalyst results.

Thesis delta

The CARDIO-TTRansform failure removes a major partnered upside leg and increases reliance on owned launches (TRYNGOLZA, zilganersen) for value creation. However, the pre-existing bear case already accounted for this risk, and management's guidance reaffirmation suggests the base-case scenario still achievable if owned products scale. The thesis shifts from a catalyst-rich pipeline story to a narrower commercial proof-point, but the $58 entry remains attractive relative to liquidity and near-term milestones.